Short answer
Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 8.01 (Other Events). First patient dosed in Phase 3 Ascend study of DT120 orally disintegrating tablet for major depressive disorder.
Definium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- First patient dosed in Phase 3 Ascend study of DT120 orally disintegrating tablet for major depressive disorder
- Clinical-stage milestone advancing DT120 toward potential registration-enabling data
- Trial initiation creates future execution risk around enrollment, efficacy, safety, and regulatory outcomes
- Press release dated May 12, 2026 provides additional study details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definium Therapeutics, Inc. 8-K filings
Get the next DFTX 8-K as it lands
Follow DFTX for push alerts, or ask the research agent what this filing means.